Q-omics provides the consensus-scored H2BC5 profile across patient tissues and cancer cell-line models. H2BC5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, H2BC5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, H2BC5 RNA expression shows 24,063 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, HNSC, and LSCC as cancer lineages where H2BC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2BC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2BC5 survival associations across molecular data types. H2BC5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2BC5 RNA expression–survival associations across cancer types. High H2BC5 expression shows unfavorable associations in LUAD, ACC, LGG and READ, but favorable associations in MESO and OV. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for H2BC5 RNA expression.
This table summarizes H2BC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for H2BC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2BC5 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, BLCA, LUAD and LIHC. The HNSC box plot shows higher H2BC5 RNA expression in tumor versus normal tissue (log2 FC = +2.038, t-test p < 0.001).
This table shows molecular features associated with H2BC5 in patient tissues and cancer cell lines. In patient samples, H2BC5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, H2BC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
